Associations of longitudinal D-Dimer and Factor II on early trauma survival risk

Background: Trauma-induced coagulopathy (TIC) is a disorder that occurs in one-third of severely injured trauma patients, manifesting as increased bleeding and a 4X risk of mortality. Understanding the mechanisms driving TIC, clinical risk factors are essential to mitigating this coagulopathic bleed...

Full description

Bibliographic Details
Main Authors: Cohen, M.J (Author), Jiang, R.M (Author), Petzold, L. (Author), Pourzanjani, A.A (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04935nam a2200805Ia 4500
001 10.1186-s12859-021-04065-z
008 220427s2021 CNT 000 0 und d
020 |a 14712105 (ISSN) 
245 1 0 |a Associations of longitudinal D-Dimer and Factor II on early trauma survival risk 
260 0 |b BioMed Central Ltd  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s12859-021-04065-z 
520 3 |a Background: Trauma-induced coagulopathy (TIC) is a disorder that occurs in one-third of severely injured trauma patients, manifesting as increased bleeding and a 4X risk of mortality. Understanding the mechanisms driving TIC, clinical risk factors are essential to mitigating this coagulopathic bleeding and is therefore essential for saving lives. In this retrospective, single hospital study of 891 trauma patients, we investigate and quantify how two prominently described phenotypes of TIC, consumptive coagulopathy and hyperfibrinolysis, affect survival odds in the first 25 h, when deaths from TIC are most prevalent. Methods: We employ a joint survival model to estimate the longitudinal trajectories of the protein Factor II (% activity) and the log of the protein fragment D-Dimer (μ g/ml), representative biomarkers of consumptive coagulopathy and hyperfibrinolysis respectively, and tie them together with patient outcomes. Joint models have recently gained popularity in medical studies due to the necessity to simultaneously track continuously measured biomarkers as a disease evolves, as well as to associate them with patient outcomes. In this work, we estimate and analyze our joint model using Bayesian methods to obtain uncertainties and distributions over associations and trajectories. Results: We find that a unit increase in log D-Dimer increases the risk of mortality by 2.22 [1.57, 3.28] fold while a unit increase in Factor II only marginally decreases the risk of mortality by 0.94 [0.91,0.96] fold. This suggests that, while managing consumptive coagulopathy and hyperfibrinolysis both seem to affect survival odds, the effect of hyperfibrinolysis is much greater and more sensitive. Furthermore, we find that the longitudinal trajectories, controlling for many fixed covariates, trend differently for different patients. Thus, a more personalized approach is necessary when considering treatment and risk prediction under these phenotypes. Conclusion: This study reinforces the finding that hyperfibrinolysis is linked with poor patient outcomes regardless of factor consumption levels. Furthermore, it quantifies the degree to which measured D-Dimer levels correlate with increased risk. The single hospital, retrospective nature can be understood to specify the results to this particular hospital’s patients and protocol in treating trauma patients. Expanding to a multi-hospital setting would result in better estimates about the underlying nature of consumptive coagulopathy and hyperfibrinolysis with survival, regardless of protocol. Individual trajectories obtained with these estimates can be used to provide personalized dynamic risk prediction when making decisions regarding management of blood factors. © 2021, The Author(s). 
650 0 4 |a adolescent 
650 0 4 |a Adolescent 
650 0 4 |a adult 
650 0 4 |a Adult 
650 0 4 |a aged 
650 0 4 |a Aged 
650 0 4 |a Aged, 80 and over 
650 0 4 |a Bayes theorem 
650 0 4 |a Bayes Theorem 
650 0 4 |a Bayesian methods 
650 0 4 |a Bayesian networks 
650 0 4 |a Biomarkers 
650 0 4 |a blood 
650 0 4 |a Clinical panel data 
650 0 4 |a Consumption levels 
650 0 4 |a D-Dimer 
650 0 4 |a Early trauma survival risk 
650 0 4 |a Factor II 
650 0 4 |a female 
650 0 4 |a Female 
650 0 4 |a fibrin degradation product 
650 0 4 |a Fibrin Fibrinogen Degradation Products 
650 0 4 |a fibrin fragment D 
650 0 4 |a Hospital settings 
650 0 4 |a Hospitals 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a injury 
650 0 4 |a Joint models 
650 0 4 |a Longitudinal models 
650 0 4 |a Making decision 
650 0 4 |a male 
650 0 4 |a Male 
650 0 4 |a middle aged 
650 0 4 |a Middle Aged 
650 0 4 |a Protein factors 
650 0 4 |a Protein fragments 
650 0 4 |a Proteins 
650 0 4 |a prothrombin 
650 0 4 |a Prothrombin 
650 0 4 |a Retrospective Studies 
650 0 4 |a retrospective study 
650 0 4 |a Risk assessment 
650 0 4 |a Risk predictions 
650 0 4 |a survival analysis 
650 0 4 |a Survival Analysis 
650 0 4 |a Trajectories 
650 0 4 |a Trauma patients 
650 0 4 |a Uncertainty analysis 
650 0 4 |a very elderly 
650 0 4 |a Wounds and Injuries 
650 0 4 |a young adult 
650 0 4 |a Young Adult 
700 1 |a Cohen, M.J.  |e author 
700 1 |a Jiang, R.M.  |e author 
700 1 |a Petzold, L.  |e author 
700 1 |a Pourzanjani, A.A.  |e author 
773 |t BMC Bioinformatics